Zobrazeno 91 - 100
of 181
pro vyhledávání: ''
Autor:
Paolo A. Ascierto, Serigne Lo, Carlo Tondini, Richard D. Carvajal, Karijn P M Suijkerbuijk, Kerry L. Reynolds, Jessica S.W. Borgers, Jeremy Lupu, Christian U. Blank, Séverine Roy, Christian Posch, Michael Erdmann, Mario Mandalà, Ines Pires da Silva, Matteo S. Carlino, Maria Grazia Vitale, Tim Cooksley, F. Stephen Hodi, Megan H. Trager, Carola Berking, Leyre Zubiri, Laura Pala, Sharon Nahm, Dirk Schadendorf, Paola Queirolo, Alon Vaisman, Neha Papneja, Paul Lorigan, Joanna Mangana, Aljosja Rogiers, Alexander M. Menzies, Thiago Pimentel Muniz, Caroline Robert, Ryan J. Sullivan, John B. A. G. Haanen, Marcus O. Butler, Reinhard Dummer, Peter Bowling, Wilson H. Miller, Osama E. Rahma, Arielle Elkrief, Samuel D. Saibil, Chiara Tentori, Joseph M. Grimes, Michael Manos, Lisa Zimmer, Georgina V. Long, April A.N. Rose, Axel Hauschild
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer
Rogiers, A, Da Silva, I P, Tentori, C, Tondini, C A, Grimes, J M, Trager, M H, Nahm, S, Zubiri, L, Manos, M, Bowling, P, Elkrief, A, Papneja, N, Vitale, M G, Rose, A A N, Borgers, J S W, Roy, S, Mangana, J, Pimentel Muniz, T, Cooksley, T, Lupu, J, Vaisman, A, Saibil, S D, Butler, M O, Menzies, A M, Carlino, M S, Erdmann, M, Berking, C, Zimmer, L, Schadendorf, D, Pala, L, Queirolo, P, Posch, C, Hauschild, A, Dummer, R, Haanen, J, Blank, C U, Robert, C, Sullivan, R J, Ascierto, P A, Miller, W H, Stephen Hodi, F, Suijkerbuijk, K P M, Reynolds, K L, Rahma, O E, Lorigan, P C, Carvajal, R D, Lo, S, Mandala, M & Long, G V 2021, ' Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition ', Journal for ImmunoTherapy of Cancer, vol. 9, no. 1, e001931 . https://doi.org/10.1136/jitc-2020-001931
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Journal for ImmunoTherapy of Cancer
Rogiers, A, Da Silva, I P, Tentori, C, Tondini, C A, Grimes, J M, Trager, M H, Nahm, S, Zubiri, L, Manos, M, Bowling, P, Elkrief, A, Papneja, N, Vitale, M G, Rose, A A N, Borgers, J S W, Roy, S, Mangana, J, Pimentel Muniz, T, Cooksley, T, Lupu, J, Vaisman, A, Saibil, S D, Butler, M O, Menzies, A M, Carlino, M S, Erdmann, M, Berking, C, Zimmer, L, Schadendorf, D, Pala, L, Queirolo, P, Posch, C, Hauschild, A, Dummer, R, Haanen, J, Blank, C U, Robert, C, Sullivan, R J, Ascierto, P A, Miller, W H, Stephen Hodi, F, Suijkerbuijk, K P M, Reynolds, K L, Rahma, O E, Lorigan, P C, Carvajal, R D, Lo, S, Mandala, M & Long, G V 2021, ' Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition ', Journal for ImmunoTherapy of Cancer, vol. 9, no. 1, e001931 . https://doi.org/10.1136/jitc-2020-001931
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
BackgroundPatients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The impact of immune checkpoint inhibition (ICI) o
Autor:
Ronny Ben-Avi, Abdullah El-Sayes, Ali A. Ashkar, Ana L. Portillo, Marianne V. Chew, Yaron Shargall, Sophie M. Poznanski, Isabella Y. Fan, Eduardo A. Rojas, Tyrah M. Ritchie
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Lung cancer remains the leading cause of cancer death worldwide despite the significant progress made by immune checkpoint inhibitors, including programmed death receptor-1 (PD1)/PD ligand 1 (PDL1)-blockade therapy. PD1/PDL1−blockade has achieved u
Autor:
Samuel P. Heilbroner, David Andrew Bender, Brigham Hyde, Simon K. Cheng, Catherine S. Spina, Catherine A. Shu, Tony J. C. Wang
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
BackgroundImmune checkpoint inhibitors (ICIs) are important new therapeutic options for the treatment of malignancy. Existing data on the relative safety of ICI treatment in patients with pre-existing autoimmune disease (AID) are limited.MethodsIn th
Autor:
Susana Banerjee, Benjamin Heyworth, Daniel Johnathan Hughes, Hannah Tharmalingam, Tom Baker, Daniel Saunders, Alison May Berner
Publikováno v:
ESMO Open
ESMO Open, Vol 5, Iss 6 (2020)
King's College London
ESMO Open, Vol 5, Iss 6 (2020)
King's College London
Introduction Over one million people in the UK identify as LGBTQ+ (lesbian, gay, bisexual, transgender, queer or questioning). Research has shown that this population experience differing cancer risk factors compared with non-LGBTQ+ patients and pers
Autor:
Priti Hegde, Shakti H. Ramkissoon, Lajos Pusztai, Kim Blenman, Brian M. Alexander, Natalie Danziger, Richard S.P. Huang, Jeffrey S. Ross, David L. Rimm, Mariya Rozenblit
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Programmed Death Ligand 1 (PD-L1) positivity rates differ between different metastatic sites and the primary tumor. Understanding PD-L1 expression characteristics could guide biopsy procedures and motivate research to better understand site-specific
Autor:
Weidong Mao, Yanhong Gu, Xiaofeng Chen, Guoqiang Wang, Yongxiang Xia, Xuehao Wang, Xiao Li, Junling Zhang, Yongqian Shu, Qianwen Shao, Jian Wang, Jun Hu, Poshita kumari Seesaha, Xiaofeng Qian, Fengjiao Zhao, Gaohua Han, Dongqin Zhu, Jing Sun, Hao Wu, Xiaofeng Wu, Changxian Li, Xiangcheng Li, Huajun Li, Yang Shao, Fei-Peng Zhu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundImmune checkpoint inhibitors monotherapy has been studied in patients with advanced biliary tract cancer (BTC). The aim of this study was to assess the efficacy and safety of camrelizumab, plus gemcitabine and oxaliplatin (GEMOX) as first-l
Autor:
Matthew H.G. Katz, Jane V Thomas, Robert A. Wolff, Michael J. Overman, Ching-Wei Tzeng, Huamin Wang, Ryan Sun, Jeffrey E. Lee, Andreina Colina, Hyunsoo Hwang, Kanwal Pratap Singh Raghav
Publikováno v:
ESMO Open
ESMO Open, Vol 5, Iss 6 (2020)
ESMO Open, Vol 5, Iss 6 (2020)
Objective Small bowel adenocarcinoma (SBA) is a rare malignancy with limited evidence regarding outcomes after curative resection of localised disease. We aimed to evaluate presentation and prognostic factors affecting overall survival (OS), relapse-
Autor:
Kerstin Schatton, Lydia Reinhardt, Dirk Schadendorf, Ulrike Keim, Jürgen C. Becker, Nora Schlecht, Andreas Meiwes, Patrick Terheyden, Carmen Loquai, Katharina C. Kaehler, Ulrike Leiter, Claudia Pfoehler, Peter Mohr, Jessica C. Hassel, Selma Ugurel, Elisabeth Livingstone, Cindy Franklin, Ralf Gutzmer, Claus Garbe, Judith Sirokay, David Rafei-Shamsabadi, Michael Weichenthal, Lena Bischof, Lisa Zimmer, Sebastian Haferkamp, Lucie Heinzerling, Albert Rübben, Valerie Glutsch, Thilo Gambichler
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
BackgroundSkin cancers are known for their strong immunogenicity, which may contribute to a high treatment efficacy of immune checkpoint inhibition (ICI). However, a considerable proportion of patients with skin cancer is immuno-compromised by concom
Autor:
Ichiro Kawada, Keita Masuzawa, Tadashi Manabe, Takahiro Karasaki, Toshiaki Ebisudani, Kazuhiro Nagayama, Masaaki Sato, Yukio Nakamura, Koji Nagaoka, Jun Nakajima, Kenzo Soejima, Tomohiro Takehara, Kazuhiro Kakimi, Ryuji Suzuki, Hirokazu Matsushita, Shinnosuke Ikemura, Yukari Kobayashi, Hiroyuki Yasuda, Kentaro Kitano, Akihiro Hosoi
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
BackgroundNot all non-small cell lung cancer (NSCLC) patients possess drug-targetable driver mutations, and response rates to immune checkpoint blockade therapies also remain unsatisfactory. Therefore, more effective treatments are still needed. Here
Autor:
Vit Drochytek, Ladislav Pecen, Ludek Sojka, Sarka Vosahlikova, Tomas Brtnicky, Michal Hensler, Tereza Lanickova, Jelena Pistolic, Jan Laco, Lorenzo Galluzzi, Vladimir Benes, Jana Rakova, Iva Truxova, Lenka Kasikova, Radek Spisek, Wolf Hervé Fridman, Ales Ryska, Ivan Praznovec, Jitka Fucikova, Irena Moserova, Karel Fiser, Petr Skapa, Catherine Sautès-Fridman, Martina Rehackova, Lukas Rob
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, BMJ Publishing Group 2020, 8 (2), pp.e000979. ⟨10.1136/jitc-2020-000979⟩
Journal for Immunotherapy of Cancer, BMJ Publishing Group 2020, 8 (2), pp.e000979. ⟨10.1136/jitc-2020-000979⟩
BackgroundThe immunological microenvironment of primary high-grade serous carcinomas (HGSCs) has a major impact on disease outcome. Conversely, little is known on the microenvironment of metastatic HGSCs and its potential influence on patient surviva